tocofersolan (Vedrop)

Advice

following a full submission

tocofersolan oral solution (Vedrop®) is not recommended for use within NHS Scotland.

Indication under review: vitamin E deficiency due to digestive malabsorption in paediatric patients suffering from congenital chronic cholestasis or hereditary chronic cholestasis, from birth (in term newborns) to 16 or 18 years of age, depending on the region.

In an open-label, single-arm study, 96% of patients had an improved or stable neurological score after 2.5 years of treatment with tocofersolan.

The manufacturer did not supply any economic analysis therefore the cost-effectiveness could not be assessed.